Age‐associated obesity and muscle atrophy (sarcopenia) are intimately connected and are
reciprocally regulated by adipose tissue and skeletal muscle dysfunction. During ageing …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide and is often associated with aspects of metabolic syndrome. Despite its …

Background & Aims An international expert panel proposed a new definition for metabolic
dysfunction–associated fatty liver disease (MAFLD) as a name change from nonalcoholic …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

This update of evidence-based guidelines (GL) aims to translate current evidence and
expert opinion into recommendations for multidisciplinary teams responsible for the optimal …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition
characterized by hepatic fat accumulation combined with underlying metabolic …

Traditionally, obesity and its related diseases have been considered a problem in Western
countries. However, in the past two decades, urbanisation in many Asian countries has led …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common forms of
chronic liver disease worldwide and its prevalence is expected to continue rising. NAFLD …

Plasma concentrations of amino acids (AAs), in particular, branched chain AAs (BCAAs), are
often found increased in nonalcoholic fatty liver disease (NAFLD); however, if this is due to …

Background & Aims We explored whether sarcopenia is associated with the histological
severity of non-alcoholic fatty liver disease (NAFLD), especially non-alcoholic steatohepatitis …